Biopsy Test Articles & Analysis

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. SOPHiA GENETICS offers a ...

By SOPHiA Genetics

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...

By SOPHiA Genetics

Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors. Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and ...

By Tethis S.p.A

New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and ...

By Guardant Health, Inc.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...

By SOPHiA Genetics

NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce ...

By miR Scientific, LLC

NEW YORK, June 3, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company dedicated to transforming global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be presenting at the Jefferies Virtual Healthcare Conference. Mr. Salman will discuss the planned commercial ...

By miR Scientific, LLC

This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...

By Exosome Diagnostics, Inc.

Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...

By BioMark Diagnostics Inc.

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Guardant Health $25 million as well as future royalties for the remaining ...

By Guardant Health, Inc.

Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...

By BioMark Diagnostics Inc.

OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 ...

By OncoDNA S.A.

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® ...

By Tethis S.p.A

Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-certification as CE-IVD as of March 22, 2021. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has ...

By Exosome Diagnostics, Inc.

Thermo Fisher Scientific has opened a call for submissions for its Oncomine Clinical Research Grant program to support clinical research. The program aims to assist educational and independent research projects that exhibit excellence in molecular profiling to advance clinical outcomes and support health care providers serving cancer patients. After initially launching the grant program in 2020, ...

By Thermo Fisher Scientific, LIMS & Laboratory Software

Lawsuit is Seen as an Attempt to Stifle Competition and Retaliate Against Guardant Health for Registering Concerns About the Antitrust Implications of Illumina’s Acquisition of Grail REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks to ...

By Guardant Health, Inc.

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...

By miR Scientific, LLC

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...

By miR Scientific, LLC

BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...

By BioMark Diagnostics Inc.

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext™ under the existing local coverage determination (LCD) (MolDX: Next-Generation Sequencing for Solid Tumors). ...

By Guardant Health, Inc.